Literature DB >> 27294341

Extrarenal Manifestations in Shigatoxin-associated Haemolytic Uremic Syndrome.

J Matthies1, C Hünseler2, R Ehren1, R Volland3, F Körber4, B Hoppe5, L T Weber1, S Habbig1.   

Abstract

BACKGROUND: Shigatoxin-associated haemolytic uremic syndrome (STEC-HUS) is the most frequent cause of acute kidney injury in children worldwide. Extrarenal manifestations are the main determinants for both, short- and long-term prognosis of patients with STEC-HUS. PATIENTS: 46 patients treated over the last 10 years for STEC-HUS in a single center.
METHODS: This retrospective study analysed the incidence and outcome of extrarenal manifestations in our cohort of children with STEC-HUS. Risk factors for extrarenal involvement and adverse outcome were assessed by detailed chart review.
RESULTS: Eleven extrarenal manifestations occurred in 9/46 patients comprising 8 neurological, 2 gastro-intestinal, and 1 cardiovascular complication. One patient died from cerebral bleeding. Liver transplantation was required in a girl 18 months after HUS due to secondary sclerosing cholangitis. PATIENTS with extrarenal manifestations were significantly younger and presented with higher leucocyte counts and higher alanine aminotransferase levels at admission. Renal replacement therapy was necessary for a longer period than in patients without extrarenal complications.
CONCLUSION: Extrarenal manifestations occurred in about 20% of our patients with STEC-HUS. The identification of risk-factors will help to provide a better management of these patients which might also include novel treatment strategies like complement inhibition. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27294341     DOI: 10.1055/s-0042-108444

Source DB:  PubMed          Journal:  Klin Padiatr        ISSN: 0300-8630            Impact factor:   1.349


  11 in total

1.  Outbreak of Shiga toxin-producing Escherichia-coli-associated hemolytic uremic syndrome in Istanbul in 2015: outcome and experience with eculizumab.

Authors:  Ayşe Ağbaş; Nilüfer Göknar; Nurver Akıncı; Zeynep Yürük Yıldırım; Mehmet Taşdemir; Meryem Benzer; İbrahim Gökçe; Cengiz Candan; Nuran Küçük; Selçuk Uzuner; Gül Özçelik; Demet Demirkol; Lale Sever; Salim Çalışkan
Journal:  Pediatr Nephrol       Date:  2018-08-29       Impact factor: 3.714

2.  Cognitive Deficits Found in a Pro-inflammatory State are Independent of ERK1/2 Signaling in the Murine Brain Hippocampus Treated with Shiga Toxin 2 from Enterohemorrhagic Escherichia coli.

Authors:  Clara Berdasco; Alipio Pinto; Mariano G Blake; Fernando Correa; Nadia A Longo Carbajosa; Ana B Celi; Patricia A Geoghegan; Adriana Cangelosi; Myriam Nuñez; Mariela M Gironacci; Jorge Goldstein
Journal:  Cell Mol Neurobiol       Date:  2022-10-13       Impact factor: 4.231

3.  SERPINB11 variant-related liver injury in STEC-HUS: case reports and literature review.

Authors:  Nazlı Umman; Mey Talip Petmezci; Çiğdem Arikan; Cansu Altuntaş; Biray Ertürk; Hasan Dursun
Journal:  Pediatr Nephrol       Date:  2022-05-12       Impact factor: 3.651

4.  A pediatric neurologic assessment score may drive the eculizumab-based treatment of Escherichia coli-related hemolytic uremic syndrome with neurological involvement.

Authors:  Paolo Giordano; Giuseppe Stefano Netti; Luisa Santangelo; Giuseppe Castellano; Vincenza Carbone; Diletta Domenica Torres; Marida Martino; Michela Sesta; Franca Di Cuonzo; Maria Chiara Resta; Alberto Gaeta; Leonardo Milella; Maria Chironna; Cinzia Germinario; Gaia Scavia; Loreto Gesualdo; Mario Giordano
Journal:  Pediatr Nephrol       Date:  2018-10-25       Impact factor: 3.714

5.  Escherichia coli-associated hemolytic uremic syndrome and severe chronic hepatocellular cholestasis: complication or side effect of eculizumab?

Authors:  Mathilde Mauras; Justine Bacchetta; Anita Duncan; Marie-Pierre Lavocat; Barbara Rohmer; Etienne Javouhey; Sophie Collardeau-Frachon; Anne-Laure Sellier-Leclerc
Journal:  Pediatr Nephrol       Date:  2019-04-08       Impact factor: 3.714

6.  Severe Acute Neurologic Involvement in Children With Hemolytic-Uremic Syndrome.

Authors:  Clare C Brown; Xiomara Garcia; Rupal T Bhakta; Emily Sanders; Parthak Prodhan
Journal:  Pediatrics       Date:  2021-02-12       Impact factor: 7.124

Review 7.  Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome.

Authors:  Patrick R Walsh; Sally Johnson
Journal:  Pediatr Nephrol       Date:  2018-07-30       Impact factor: 3.714

8.  Therapeutic Strategies to Protect the Central Nervous System against Shiga Toxin from Enterohemorrhagic Escherichia coli.

Authors:  Jorge Goldstein; Krista Nuñez-Goluboay; Alipio Pinto
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

9.  Peripheral nervous system manifestations of Shiga toxin-producing E. coli-induced haemolytic uremic syndrome in children.

Authors:  Luisa Santangelo; Giuseppe Stefano Netti; Elena Ranieri; Mario Giordano; Diletta Domenica Torres; Giovanni Piscopo; Vincenza Carbone; Luciana Losito; Leonardo Milella; Maria Luigia Lasorella; Pasquale Conti; Delio Gagliardi; Maria Chironna; Federica Spadaccino; Elena Bresin; Antonio Trabacca
Journal:  Ital J Pediatr       Date:  2021-09-06       Impact factor: 2.638

Review 10.  Valid Presumption of Shiga Toxin-Mediated Damage of Developing Erythrocytes in EHEC-Associated Hemolytic Uremic Syndrome.

Authors:  Johanna Detzner; Gottfried Pohlentz; Johannes Müthing
Journal:  Toxins (Basel)       Date:  2020-06-04       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.